Phase I Multicenter Trial Combining Nivolumab, Ipilimumab and Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
Phase I Multicenter Trial Combining Nivolumab, Alone or With Ipilimumab, Plus Hypo-fractionated Radiotherapy for Pretreated Advanced Stage Non-small Cell Lung Cancer Patients
Sponsor: Assistance Publique Hopitaux De Marseille
Terminated
SAFETY
Other terminated trials from Assistance Publique Hopitaux De Marseille
- Bariatric Surgery · Phase NA · May 2024
- Psoriasis · Phase PHASE4 · Feb 2024
- Persistent ARDS · Phase PHASE3 · Nov 2023
- Paraganglioma · Phase NA · Oct 2023
- Epilepsy · Phase NA · Jun 2023
See all terminations from Assistance Publique Hopitaux De Marseille
Other Non-small Cell Lung Cancer trials with similar outcome
A PHASE1 clinical study on Non-small Cell Lung Cancer, this trial is terminated or withdrawn. The trial is conducted by Assistance Publique Hopitaux De Marseille and has accumulated 8 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jul 2023 — Jul 2024 [monthly]
Terminated PHASE1
-
Dec 2022 — Jul 2023 [monthly]
Terminated PHASE1
Status: Unknown Status → Terminated
-
Oct 2021 — Dec 2022 [monthly]
Unknown Status PHASE1
Status: Not Yet Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Not Yet Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Assistance Publique Hopitaux De Marseille
For direct contact, visit the study record on ClinicalTrials.gov .